PHAL: Phal-501 shows promise for heavy metal detox; funding secured, but more needed by 2025

About this update from Pharmalundensis Ab

PharmaLundensis advanced Phal-501 for heavy metal detox, showing new efficacy against cadmium, and raised SEK 2.83 million net in a rights issue. Ongoing clinical and cleantech initiatives require further funding by spring 2025.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmalundensis Ab